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Abstract We recently reported that transgenic mice with
cardiac-restricted overexpression of CCN2/CTGF have sub-
stantially increased tolerance towards ischemia/reperfusion
injury. The purpose of this study was to investigate to what
extent fully differentiated cardiac myocytes are direct targets
of CCN2, and to resolve the signaling mechanisms that
convey the cardioprotective actions of CCN2. Akt and
GSK-3β were identified as putative intermediaries of intra-
cellular signaling stimulated by recombinant human CCN2
(rhCCN2). Concentration-effect experiments revealed
CCN2-stimulated phosphorylation of Akt (Ser473) and
downstream GSK-3β (Ser9) with EC50 ~250 nmol/L.
CCN2-stimulated phosphorylation of Akt and GSK-3β
was sensitive to inhibition of PI3-kinase (LY294002).
Phosphorylation of GSK-3β was also sensitive to Akt-
inhibition (API-2), demonstrating CCN2-engendered activa-
tion of a PI3-kinase/Akt/GSK-3β-signaling pathway. A
C-terminal peptide fragment of CCN2 (11.2 kD) displayed
partial agonist activity, while two short peptides derived
from the Thrombospondin- and the IGFBP- homology
domains of CCN2, respectively, additively inhibited
rhCCN2-stimulated Akt-phosphorylation. The viability of
cardiac myocytes subjected to hypoxia/reoxygenation injury
or doxorubicin-induced oxidative stress was assessed by
assays of adenylate kinase and lactate dehydrogenase re-
leased from dying cells. Cardiac myocytes exposed to
CCN2 displayed increased tolerance towards hypoxia/reox-
ygenation and doxorubicin-induced oxidative stress, an ef-
fect that was abrogated by inhibition of PI3-kinase. The
cytoprotective actions of CCN2 reflected in the transcrip-
tome of CCN2-stimulated cardiac myocytes (anti-apoptosis,
stress, and wound-response gene programs). In conclusion,
this study discloses the novel findings that cardiac myocytes
are CCN2 target cells in which CCN2 increases tolerance
towards hypoxia and oxidative stress via PI3-kinase-
dependent Akt/GSK-3β signaling.
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CCN2/CTGF, connective tissue growth factor, is a secreted,
matricellular protein that belongs to the CCN family (acro-
nym for the first three recognized members of this family;
Cyr61/CTGF/Nov). The CCN proteins are involved in a
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wide array of cellular and more complex biologic functions
depending on cellular context (for review, see Brigstock et
al. (Rachfal and Brigstock 2005)). As alluded to by its name,
increased tissue contents of CCN2 is often found in con-
ditions associated with fibrosis as in wound healing with
scar formation or inflammatory disorders with increased
production of collagen (Chuva de Sousa Lopes et al.
2004). However, it has not yet been demonstrated that
CCN2 is a bona fide growth factor sufficient to elicit fibrosis
by itself. Indeed, genetically-engineered mice with in-
creased tissue expression of CCN2, as well as other studies,
indicate that CCN2 by itself is not sufficient to elicit fibrosis
(Ahmed et al. 2011; Chujo et al. 2009; Nakanishi et al.
2001). Rather, additional factors appear to be required for
fibrosis (Chujo et al. 2009). CCN2 is highly expressed in the
developing heart, and can be identified in endothelial cells,
cardiac fibroblasts, as well as cardiac myocytes (Chuva de
Sousa Lopes et al. 2004). However, in the postnatal heart
CCN2 is more or less completely repressed. Several studies
have reported substantial induction of myocardial CCN2 in
heart failure of various etiologies (Chen et al. 2000; Ahmed
et al. 2005). Yet, the role of CCN2 in the pathophysiologic
mechanisms of heart failure remains largely unknown. Data
indicating that CCN2 may act as a cell survival factor have
prompted studies attempting to resolve the role of CCN2 in
ischemia/reperfusion injury. In two reports of transgenic
mice with cardiac-restricted overexpression of CCN2, the
first report did not find altered tolerance of hearts over-
expressing CCN2 towards ischemia/reperfusion injury,
whereas the later study reported robust increase of tolerance
towards ischemia/reperfusion injury of CCN2-expressing
hearts (Panek et al. 2009; Ahmed et al. 2011). Apparently,
overexpression of CCN2 was substantially higher in the
hearts displaying increased tolerance towards ischemia/
reperfusion injury. Corroborating the evidence of a cardio-
protective function of CCN2 was also the observation that
rhCCN2 reduced infarct size of ex vivo-perfused hearts
subjected to ischemia/reperfusion injury (Ahmed et al.
2011). However, to what extent the cardioprotective prop-
erties of CCN2 could be elicited by direct action on cardiac
myocytes was not investigated. The CCN proteins are as-
sumed to function by interaction with extracellular matrix
proteins. Although a cognate receptor for CCN2, or any of
the other CCN proteins, has not yet been convincingly
identified, several reports indicate that CCN proteins may
also interact with plasma membrane proteins, e.g. integrin
receptors or LRP5/6 (LDL receptor-associated protein-5/6)
(Rachfal and Brigstock 2005). Furthermore, the intracellular
signaling pathways of CCN2 have not yet been properly
characterized, although intracellular signaling mechanism
may vary with cell type or cellular context (Rachfal and
Brigstock 2005). The major objectives of this study were 1)
to investigate to what extent the cardioprotective properties
reported for CCN2 could be based on direct cytoprotective
actions of CCN2 on adult cardiac myocytes exposed to
hypoxia/reoxygenation, i.e. simulated ischemia/reperfusion
injury, 2) to identify the intracellular signaling pathways of
CCN2 in the terminally differentiated, adult cardiac myo-
cyte, and 3) to resolve to what extent the identified signaling
mechanisms and resultant transcriptome were involved in
the cytoprotective actions of CCN2.
Materials and methods
Reagents Recombinant full-length, human CCN2
(rhCCN2) was contract-purified from the cell culture
medium of transfected HEK 293 cells by EMP
Genetech (Germany), essentially as previously described
(Ahmed et al. 2004). The purified protein was resolved
by sodium dodecylsulphate polyacrylamide gel electro-
phoresis (SDS-PAGE), and the homogeneity and integrity
of the protein was assessed by Coomassie brilliant blue stain-
ing of the gel and by Western blot analysis. rhCCN2
was subjected to deglycosylation under non-denaturing
conditions using Protein Deglycosylation Mix (Endo-α-N-
Acetylgalactosaminidase, PNGase F, Neuraminidase, β1-4
Galactosidase, β-N-Acetylglucosaminidase) provided by
New England Biolabs Inc. (MA, USA). rhCCN2, Reaction
Buffer, and enzyme cocktail were mixed, and the reaction was
subsequently incubated at 37 °C for four hours. rhCCN2 was
also subjected to heat-treatment, as an eppendorf tube con-
taining rhCCN2 was placed in boiling water for 15 min. The
recombinant 11.2 kD C-terminal fragment of human CCN2
was from Peprotech EC Ltd. (UK). Synthetic peptides derived
from the primary sequence of human CCN2 (GenBank ID:
CAG46559) were custom-made from GenScript Inc. (NJ,
USA). The peptides were P1, amino acids 200–224
(LVQTTEWSACSKTCGMGISTRVTND), from the
Thrombospondin homology domain and P2, amino acids
47–66 (VSLVLDGCGCCRVCAKQLGE), from the
Insulin-like growth factor binding protein-like (IGFBP)
homology domain of human CCN2. All antibodies were
purchased from Cell Signaling Technology, Inc. (MA,
USA). The selective phosphatidylinositol 3-kinase (PI3-ki-
nase) inhibitor LY294002, its corresponding negative control
compound LY303511, and the selective Akt inhibitor API-2
were from Tocris Bioscience Inc. (MO, USA). Ad-GRK2ct,
recombinant adenovirus encoding carboxyl terminal fragment
of GRK2/βARK1, was kindly provided by Dr. Walter J.
Koch, Jefferson Medical College, Philadelphia, USA
(Drazner et al. 1997).
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Isolation of adult cardiac myocytes and maintenance of
primary cultures Ca2+-tolerant cardiac myocytes were iso-
lated from mouse hearts (C57/BL6 mice, 10–16 weeks of
age) by coronary perfusion with collagenase type 2
(Worthington Biochemical Corp., NJ, USA) as described
by O’Connell et al. (O’Connell et al. 2007). The cells were
plated in laminin-coated tissue culture wells (Invitrogen
Inc., CA, USA) in Minimum Essential Medium (MEM)
with Hanks’ Balanced Salt Solution (HBSS), supplemented
with 10 % serum, 100 U/mL penicillin-G, 2 mmol/L ATP,
and 10 mmol/L 2,3-butanedione monoxime (BDM). After
two hours the plating medium was replaced with culture
medium (MEM with HBSS, supplemented with 0.1 % bo-
vine serum albumin (BSA), 100 U/mL penicillin-G, and
10 mmol/L BDM). The cardiac myocytes were maintained
in primary culture for up to 72 h in humidified atmosphere
containing 2 % CO2. All animal studies were performed in
accordance with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (NIH Pub. No. 85–23, revised 1996) and were ap-
proved by the Chief Veterinarian of the Vivarium at Oslo
University Hospital- Rikshospitalet and the national board for
animal research, the Norwegian Animal Research Authority.
Analysis of protein- and phosphoprotein levels For Western
blot analysis, extracts of cardiac myocytes were prepared in
solubilization buffer containing 10 mmol/L Tris–HCl (pH
7.4), 1 % SDS, 10 mmol/L NaF, and 2 mmol/L Na3VO4.
The samples were denatured in Laemmli buffer, and separated
by 12 % SDS-PAGE. The PVDF membrane was blocked in
Tris-buffered saline (TBS) with 0.1 % Tween-20 and 5 %
nonfat dry milk, and subsequently incubated with primary
antibody in TBS with 0.1 % Tween-20 and 5 % BSA.
Horseradish peroxidase-conjugated anti-rabbit IgG was used
as secondary antibody, and the protein bands were visualized
with the chemiluminescent substrate LumiGLO Reserve
(KPL Inc., MD, USA). Protein/phosphoprotein levels in cell
lysates from Rat-2-Fibroblasts, COS-7 cells, CHO cells, or
HEK 293 cells stimulated with rhCCN2, deglycosylated
rhCCN2, heat-treated rhCCN2, or C-peptide were determined
by ELISA using the Luminex technology (Bio-Rad
Laboratories Inc., CA, USA). Briefly, antibody coupled beads
were added to wells of a 96-well plate, the wells were washed,
and thereafter incubated with cell lysates for 30min. Thewells
were washed again, and biotin-labeled detection antibodies
were added. After another wash, the wells were incubated
with fluorophore-labeled streptavidin reporter before record-
ing in the Bio-Plex array reader.
Doxorubicin induced oxidative stress Cardiac myocytes
were preincubated in the absence or presence of 200 nmol/L
rhCCN2 for 20 h. Subsequently, the cells were exposed to
15 μmol/L doxorubicin (Tocris) for additional 20 h before
analysis of markers of cell damage.
Hypoxia/Reoxygenation-induced cell death Cardiac myo-
cytes were preincubated in the absence or presence of
rhCCN2 (200 nmol/L) for 20 h and subsequently subjected
to consecutive cycle of hypoxia and reoxygenation in order
to simulate the ischemia/reperfusion injury of tissues fol-
lowing transient occlusion of blood supply. After the pre-
incubation, the cell culture medium was replaced with
glucose-free cell culture medium pre-equilibrated with 1 %
O2 and then, the cells were incubated in a hypoxia chamber
(1 % O2, 2 % CO2, and 97 % N2) for four hours followed by
reoxygenation (21 % O2, 2 % CO2, 77 % N2) for 1 h.
Assays of cardiac myocyte cell death and viability Cell
death was assessed by analysis of adenylate kinase (AK)
and lactate dehydrogenase activities (LDH) released into the
cell culture medium from dying cells. Both AK and LDH
release assays are established methods for assessment of cell
viability based on the principle that cell death leads to
increase of membrane permeability and effusion of cyto-
plasmic enzymes into the extracellular medium (Aras et al.
2008; Crouch et al. 1993). AK activities in the cell culture
medium were determined by the ToxiLight assay (Lonza
Group Ltd., Switzerland) according to the manufacturer’s
instructions. Samples of cell culture medium were trans-
ferred into a 96-well plate (20 μL/well), and 100 μL/well
of AK Detection Reagent was added. Luminescence was
recorded by a microplate reader (F12900 GENios, Tecan
Group Ltd., Switzerland). Release of LDH activities from
dying cardiac myocytes were quantified using the
Cytotoxicity Detection Kit (Roche Ltd., Switzerland). Cell
culture medium was sampled and centrifuged, and the su-
pernatant (100 μL) was mixed with 100 μL of the reaction
mixture according to the manufacturer’s instructions.
Absorbance was measured at 492 nm (reference wavelength
630 nm) with a microplate reader. Serial dilutions of cell
culture medium disclosed linear correlations between sam-
ple amount and AK and LDH activities assayed. Assay of
cell viability was performed by assessing release of either of
the enzymes in cells treated with rhCCN2 versus cells
exposed to vehicle relative to total enzyme release in
complete-kill wells and calculated according to previously
published methodology as follows (Aras et al. 2008):
% cell viability ¼ 1 Eimean vehicle resultð Þ= mean complete kill resultmean vehicle resultð Þ½ f g  100
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In the above equation Ei refers to enzyme release in
individually treated wells, i.e. the CCN2-treated wells.
Complete lysis of cardiac myocytes was achieved in 1 %
Triton X-100.
TUNEL assay of apoptosis Apoptosis of cardiac myocytes
was determined by terminal deoxynucleotidyl transferase
dUTP nick end labeling (TUNEL). Cells were seeded in
6-well plates and subjected to hypoxia/reoxygenation as
described above. TUNEL staining was performed using
the In Situ Cell Death Detection Kit (Roche) according to
the manufacturer’s instructions, and analyzed by fluores-
cence microscope (Axiovert S100, Carl Zeiss, Germany).
TUNEL positive cells and total number of cells (Hoechst-
stained) were counted. A minimum of ten visual fields per
well were randomly selected and analyzed.
RNA purification Total RNAwas isolated using the RNeasy
system (Qiagen, Germany). The amount and quality of the
extracted RNAwere measured by both a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, DE, USA) and a
Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA).
Analysis of gene expression RNA was reverse transcribed
with TaqMan Reverse Transcription Reagents Kit. Real-
time quantitative PCR was run in triplicates for each sample,
using TaqMan Pre-Developed Assay Reagents and The ABI
Prism 7900 Sequence Detection System and software
(Applied Biosystems, CA, USA), according to the manu-
facturer’s instructions.
DNA microarray analysis Cardiac myocytes were cultured
in the absence (n06) or presence (n06) of 200 nmol/L
rhCCN2 for 48 h. Total RNA was subjected to genome-
wide expression analysis using Illumina gene expression bead
arrays. MouseWG-6 v2 bead chips (Illumina Inc., CA, USA)
with 48,000 transcripts were used. RNAwas amplified using
the Illumina TotalPrep-96 RNA Amplification Kit (Ambion
Inc., TX, USA) with 500 ng of total RNA as input material.
cRNAwas synthesized overnight (14 h), labeled, and hybrid-
ized to the chips at 58 °C overnight, according to the manu-
facturer’s protocol. After hybridization and stringent wash, the
chips were stained with streptavidin-Cy3 (GE Healthcare,
UK) and scanned with an Illumina bead array reader. The
scanned images were imported into BeadStudio 3.1.3.0
(Illumina Inc.) for extraction, quality control, and quantile
normalization. Data were log2 transformed, and a moderated
t-statistic was used for significance analysis. A list of differ-
entially expressed genes was generated using topTable
(Illumina), and the false discovery rate was controlled by
Benjamini and Hochberg’s method. The annotation file
MouseWG-6_V2_0_R2_11278593_A.bgx was used. Gene
Ontology analysis was performed to look for terms that were
overrepresented in the list of differentially expressed genes. A
statistical comparison between the differentially expressed
genes (q-value <0.01) and the whole data set was conducted
by Fisher’s exact test, and p-values were Bonferroni corrected
for multiple comparisons. Microarray data were deposited at
GEO-NCBI with the following accession number:
GSE36073. (The microarray service was provided by
Norwegian Microarray Consortium, supported by the func-
tional genomics program of the Research Council of Norway.)
Statistical analysis The experimental groups were assessed
by two-tailed un-paired Student’s t test. P values <0.05 were
considered statistically significant. For multiple compari-
sons one-way ANOVAwas performed, and post-hoc analy-
sis with Bonferroni’s test was employed.
Results
CCN2 activates the PI3-kinase/Akt/GSK-3β salvage kinase
pathway Stimulation of adult cardiac myocytes with
rhCCN2 (100 and 250 nmol/L) revealed robust increase in
phospho-Akt (Ser473) and phospho-GSK-3β (Ser9) activi-
ties. On the other hand, stimulation of cardiac myocytes
with rhCCN2 did not alter phospho-JNK (Thr183/Tyr185),
phospho-P38 (Thr180/Tyr182), phospho-ERK1/2 (Thr202/
204), phospho-ERK5 (Thr218/Tyr220), phospho-TrkA
(Tyr490), phospho-Smad1/2/3 (Ser463/465/467/423/425),
or phospho-Stat3 (Tyr705) levels in cardiac myocytes
(Fig. 1a shows western blots and Fig. 1b densitometric
analysis). Western blot analysis with site-specific phospho-
serine antibodies revealed concentration-dependent increase
of phospho-Akt (Ser473) (Fig. 2a) and phospho-GSK-3β
(Ser9) (Fig. 2b) in cardiac myocytes stimulated with
rhCCN2. Consistent with the phosphorylation of GSK-3β
at serine-9 and ensuing inhibition of GSK-3β activities,
rhCCN2 led to reduced levels of phospho-glycogen syn-
thase (GS) (Ser641) in cardiac myocytes (Fig. 2c). CCN2-
stimulated phosphorylation of Akt and GSK-3β was sensi-
tive to inhibition of PI3-kinase by LY294002 (Fig. 3a and
b), and complete inhibition of CCN2-stimulated phosphor-
ylation of Akt and GSK-3β was observed with LY294002 at
50 μmol/L. Phosphorylation of GSK-3β (Ser9) was also
sensitive to inhibition of Akt with the Akt-selective inhibitor
API-2 (1–10 μmol/L) (Fig. 3c). Inhibition of CCN2-
stimulated phosphorylation of GSK-3β by both LY294002
and API-2 provides strong evidence of a CCN2-stimulated
intracellular PI3-kinase/Akt/GSK-3β-signaling pathway in
cardiac myocytes. p70s6K, a kinase downstream of Akt,
was also phosphorylated by CCN2 and its activation was
sensitive to PI3-kinase inhibition with LY294002 (Fig. 3d).
To further investigate the mechanisms of CCN2-induced
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activation of Akt, competitive inhibition of the pleckstrin
homology (PH) domain of Akt was tested by means of
recombinant adenovirus-mediated transduction of the
carboxyl-terminal region of G protein-coupled receptor
kinase-2 (GRK2ct) in cardiac myocytes. Expression of
GRK2ct, containing a prototypical PH-domain, substantial-
ly attenuated CCN2-stimulated phospho-Akt (Ser9) levels
in cardiac myocytes, providing evidence of a PH domain-
mediated plasma membrane targeting mechanism in activa-
tion of Akt by CCN2 (Fig. 3e and f).
For investigation of the efficacy and potency of rhCCN2
in activation of Akt/GSK-3 signaling, Rat-2 fibroblasts were
employed and stimulated in the presence of an extended
range of concentrations of CCN2. ELISA (Bio-Plex/
Luminex) disclosed concentration-dependent increase of
phospho-Akt (Ser473) and phospho-GSK-3α/β (Ser21/
Ser9) levels in stimulated cells, with half-maximal effects
(EC50) of rhCCN2 at approximately 200 nmol/L. Maximal
responses of rhCCN2 were obtained at concentrations be-
tween 500 nmol/L and 1 μmol/L. (Fig. 4a and b). rhCCN2
also stimulated increase of phospho-Akt (Ser473) and
phospho-GSK-3α/β (Ser21/9) levels in COS-7 cells, CHO
cells, and HEK 293 cells (data not shown).
Deglycosylated and heat-treated rhCCN2 activates Akt and
GSK-3α/β The purified rhCCN2 was essentially homoge-
nous as assessed by SDS-PAGE and subsequent staining of
the gel with Coomassie brilliant blue (Fig. 5a, lane 1).
Western blot analysis revealed that purified, rhCCN2 mi-
grated as two bands with molecular mass around 38–40 kD,
both of which displayed strong immunoreactivity against
anti-CCN2 antibody (Fig. 5a, lane 2). rhCCN2 has previ-
ously been reported to migrate as two discrete bands of
approximate molecular mass 38–40 kD, with alteration of
electrophoretic mobility after deglycosylation (Bohr et al.


























aFig. 1 a. Western blots of
indicated phospho-protein lev-
els and total protein levels in
cardiac myocytes stimulated
with 100 nmol/L or 250 nmol/L
rhCCN2 for 30 min. Figure
demonstrates three replicate
lanes of each treatment (control/
stimulation). The Western blot
images are all representative of
three independent experiments.
b. Densitometric analysis of
Western blots in a. Histograms
show phospho-protein levels
relative to total protein con-
tents. Data are mean ± SEM of
n03 in each group, *p<0.05 vs
control
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p-JNK (Thr183/Tyr184) p-p38 (Thr180/Tyr182)
p-ERK1 (Thr202/Tyr204) p-ERK2 (Thr202/Tyr204)
p-ERK5 (Thr218/Tyr220) p-TrkA (Tyr490)
p-Smad1 (Ser463/465) p-Smad2 (Ser465/467)
p-Smad3 (Ser423/425) p-Stat3 (Tyr705)
CCN2 Control 100 nM CCN2 250 nM CCN2
Control 100 nM CCN2  lortnoC2NCC Mn 052 100 nM CCN2 250 nM CCN2
Control 100 nM CCN2 250 nM CCN2 Control 100 nM CCN2 250 nM CCN2
Control 100 nM CCN2 250 nM CCN2 Control 100 nM CCN2 250 nM CCN2







































p-Akt (Ser 473) p-GSK-3 β (Ser 9)
Control 100 nM CCN2 250 nM CCN2 Control 100 nM CCN2 250 nM CCN2
bFig. 1 (continued)
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conditions by enzymatic reactions, and deglycosylation was
confirmed by mobility shift on SDS-PAGE (Fig. 5b). As
shown in Fig. 4a and b, the potency and efficacy of degly-
cosylated rhCCN2 were similar to those of native, glycosy-
lated rhCCN2 in phosphorylation of Akt (Ser473) and GSK-
3α/β (Ser21/Ser9) in Rat-2-fibroblasts, indicating that gly-
cosylation of CCN2 is not essential for stimulation of the
intracellular Akt/GSK-3β signaling pathway. Likewise,
heat-treated rhCCN2 stimulated phosphorylation of Akt and
GSK-3α/β with similar efficacy and potency as native
rhCCN2 (Fig. 4c and d). In contrast, rhCCN2 pretreated with
the strong reducing agent dithiothretiol (DTT, 10 mmol/L)
was not able to phosphorylate Akt (data not shown),
suggesting that the activity of CCN2 is dependent on intact
disulfide bonds.
Peptides derived from the primary sequence of CCN2 with
agonist or antagonist activity The 11.2 kD C-terminal pep-
tide fragment of human CCN2 (C-peptide) displayed partial
agonist activity compared with full-length rhCCN2 at
phosphorylation of Akt (Ser473) (Fig. 4e) and GSK-3α/β
(Ser21/Ser9) (Fig. 4f) in Rat-2-fibroblasts. The C-peptide
was also substantially less potent than the native protein.
The peptides derived from the Thrombospondin-homology
(P1) and the IGFBP-homology (P2) domains of CCN2
(Fig. 6b) did not display agonist activity in terms of capacity
to stimulate phosphorylation of Akt (Ser473) (data not
shown). However, both peptides inhibited CCN2-stimulated
phosphorylation of Akt (Ser473), and the inhibitory actions of
P1 and P2 were additive (Fig. 6a).
rhCCN2 increases tolerance towards doxorubicin-induced
oxidative stress and hypoxia/reoxygenation injury in cardi-
ac myocytes The effects of rhCCN2 on viability of adult
cardiac myocytes following hypoxia/reoxygenation and ox-
idative stress were investigated. Incubation of cardiac myo-
cytes in the presence of rhCCN2 (200 nmol/L) protected
cardiac myocytes against doxorubicin-induced oxidative
stress and cell death as demonstrated by reduced release of































































































Fig. 2 Activation of Akt/GSK-3β signaling pathway by CCN2. a
Western blot analysis of phospho-Akt (Ser473) and b phospho-GSK-
3β (Ser9) contents in cardiac myocytes stimulated with increasing
concentrations of rhCCN2 for 30 min. c Western blot analysis of
phospho-glycogen synthase (Ser641) levels in cardiac myocytes
stimulated with 250 nmol/L rhCCN2 for 24 and 40 h. The histograms
demonstrate densitometric analysis of phospho-protein levels relative
to respective total protein contents. Data are mean ± SEM of n03 in
each group, *p<0.05 vs. control. The figure is representative of three
independent experiments
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rhCCN2 increased survival (viability) of cardiac myocytes
exposed to hypoxia/reoxygenation (Fig. 7b).
PI3-kinase inhibition abolishes the cytoprotective effect of
rhCCN2 To investigate to what extent PI3-kinase/Akt sig-
naling pathways were involved in the CCN2-mediated pro-
tective mechanisms, cardiac myocytes were stimulated with
rhCCN2 in the absence or presence of the PI3-kinase inhib-
itor LY294002, and then subjected to hypoxia/reoxygena-
tion injury. As shown in Fig. 8a and b, inhibition of PI3-
kinase abolished the cytoprotective effects of rhCCN2, in-
dicating that the protective effect of rhCCN2 in cardiac
myocytes is mediated by PI3-kinase/Akt. The negative con-
trol compound, LY303511, with respect to the PI3-kinase
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Fig. 4 Comparison of efficacy
of deglycosylated rhCCN2,
heat-treated rhCCN2, and
C-peptide with native rhCCN2.
Concentration-effect curves of
deglycosylated rhCCN2 (a-b),
heat-treated (c-d), and C-
peptide (e-f) compared with
rhCCN2 in Rat-2–fibroblasts.
The phosphoprotein levels were
examined by Bio-Plex/Lumi-
nex. Each point is mean ± SEM
(n03)
Fig. 3 CCN2-mediated activation of Akt/GSK-3β signaling pathway is
sensitive to PI3-kinase- and Akt-inhibiton. a Western blot analyses of
phosphoprotein and total protein levels of Akt, b-c GSK-3β, and d
p70S6K in cardiac myocytes incubated for 15 min without (Control) or
with 100 nmol/L rhCCN2 (CCN2), or with 100 nmol/L rhCCN2 in the
presence of the PI3-kinase inhibitor LY294002 (CCN2 + LY) or in
presence of the Akt inhibitor API-2 (CCN2 + API-2). e Inhibition of
phospho-Akt (Ser473) activities by competitive inhibition of pleckstrin
homology (PH) domain of Akt by expression of GRK2ct. Western blot
demonstrating phospho-Akt (Ser473) and total Akt levels in cardiac
myocytes expressing GRK2ct or LacZ in the absence or presence of
rhCCN2. Cells were incubated for 40 h after infection with Ad-GRK2ct
or Ad-LacZ at 1,000× multiplicity of infection (MOI), then stimulated
with rhCCN2 (100 nmol/L) for 30 min. f Western blot analysis of
GRK2ct expression in cardiac myocytes 40 h after infection with 1,000
MOI Ad-GRK2ct or Ad-LacZ. The histograms demonstrate densitomet-
ric analysis of indicated phospho-protein activities relative to total con-
tents of the respective proteins. Data aremean ± SEM, n03 in each group,
*p<0.05. The figure is representative of three independent experiments

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viability (Fig. 8a and b). TUNEL-staining of cardiac myo-
cytes exposed to hypoxia/reoxygenation showed decreased
number of apoptotic cells in samples preincubated in the
presence of rhCCN2 (200 nmol/L) (Fig. 8c). Figure 8d and e
show examples of TUNEL positive and negative cardiac
myocytes, respectively.
Analysis of the transcriptome of cardiac myocytes stimulat-
ed with rhCCN2 Illumina gene expression bead arrays
(MouseWG-6 v2 bead chips) were used to analyze the tran-
scriptome of cardiac myocytes incubated in the absence or
presence of rhCCN2 (200 nmol/L) for 48 h. The total
number of genes analyzed was 38,805. Based on statistical
analysis with a moderated t-statistic (Benjamini and
Hochberg’s method to control the false discovery rate),
6,476 genes were found to be significantly up- or down-
regulated in cells stimulated with CCN2. Gene ontology
analysis revealed that genes included under the terms
“Anti-apoptosis” (P00.01; a subordinate of “Apoptosis-re-
lated genes” (P01.6*10−5)), “Response to wounding” (P0
2.6*10−8), and “Response to stress” (P03.8*10−5) were
significantly overrepresented in cardiac myocytes exposed
to rhCCN2. Graphical presentation of the genes included
under these terms is provided by heat maps illustrating the
relative expression levels of these genes (Fig. 9 and 10). A
listing of the top 15 genes displaying the greatest fold up- or
down-regulation is presented in Table 1. Several of the most
highly up-regulated genes in this list have previously been
reported to exert cardioprotective actions and increase tol-
erance towards ischemia/reperfusion injury, i.e. WISP1
(CCN4), GDF15, and lipocalin-2 (Venkatesan et al. 2010;
Xu et al. 2006; Roudkenar et al. 2009), or activate cellular
prosurvival mechanisms (the dual specificity tyrosine
phosphorylation-regulated kinase DYRK3) (Guo et al.
2010). Up-regulation of these genes in cardiac myocytes
stimulated with rhCCN2 for 48 h were confirmed by real-
time qPCR using sequence specific Taqman probes
(Fig. 11). CCN2-stimulated induction of WISP1 and
GDF15, among others on the top-15 list, was also found to
be sensitive to inhibition of Akt with API-2, demonstrating
that the transcriptome of CCN2-stimulated cardiac myo-
cytes at least in part reflected activation of Akt signaling
pathways (Fig. 11). However, CCN2-stimulated increase of
lipocalin-2 and DYRK3 mRNA expression did not appear


























































































IGFBP domain (72 AA)
GAPCIFGGTVYRSGESFQSSCKYQCTCLDGAVGCMPLCSMDVRLPSPDCPFPRRVKLPGKCCEEWVCD
     VWC domain (68 AA) 
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TSP domain (52 AA)
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MFIKTCACHYNCPGDNDIFESLYYRKMYGDMA
CT domain (98 AA)
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Fig. 6 a Phospho-Akt levels in Rat-2-fibroblasts stimulated in the
absence or presence of rhCCN2 (50 nmol/L) for 30 min, or co-
incubated with P1 and/or P2 in two different concentrations
(12.5 μmol/L (μM) and 50 μmol/L) together with rhCCN2 (50 nmol/
L). Phosphoprotein activities were analyzed by Bio-Plex/Luminex.
Each point is mean ± SEM (n03). *p<0.05 vs. CCN2, †p<0.05 vs.
CCN2 +12.5 μmol/L P1 and vs. CCN2 +12.5 μmol/L P2, #p<0.05 vs.
CCN2 +50 μmol/L P1. b Diagram of the modules of CCN2, with the
peptides derived from the Thrombospondin-homology (P1) and the












Fig. 5 Assessment of integrity and homogeneity of rhCCN2. a Puri-
fied recombinant human CCN2 resolved by SDS-PAGE and stained
with Coomassie brilliant blue (lane 1) or subjected to Western blot
analysis (lane 2). b Coomassie staining of native rhCCN2 (Control)
and deglycosylated rhCCN2 (Deglycos.)
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Discussion
The present study discloses the novel findings that
CCN2 increases the tolerance of adult, fully differenti-
ated cardiac myocytes towards hypoxia/reoxygenation-
induced oxidative stress and cell death. The cytoprotec-
tive effect of CCN2 was engendered by direct action on
cardiac myocytes and was also supported by activation
of stress response- and anti-apoptotic gene programs.
The principal signaling pathway that conferred the cyto-
protective actions of CCN2, was a PI3-kinase sensitive Akt/
GSK-3β signaling pathway.
In a recent report we demonstrated that CCN2
increases the tolerance of the heart towards ischemia/
reperfusion injury both in transgenic mice with cardiac-
restricted overexpression of CCN2, as well as in ex
vivo perfused mouse hearts exposed to rhCCN2
(Ahmed et al. 2011). However, an issue not yet re-
solved, was to what extent CCN2 acted through modu-
lation of extracellular matrix protein functions, or rather
exerted its cardioprotective effects by direct action on
cardiac myocytes. Despite the fact that a receptor for
CCN2 has not yet been properly characterized, the
current study reveals that cardiac myocytes are direct
targets of rhCCN2. The conclusion that the Akt/GSK-
3β phosphokinase cascade was the relevant signaling
pathway in the CCN2-mediated cytoprotection was sup-
ported by several observations. First, phosphorylation of
Akt at Ser473 and GSK-3β at Ser9 were the only
robustly regulated phosphokinases detected in cardiac
myocytes stimulated with rhCCN2. Second, Akt-
mediated phosphorylation of GSK-3β at Ser9 with sub-
sequent inhibition of GSK-3β, reflected in reduced
phosphorylation of glycogen synthase, a canonical sub-
strate of GSK-3β. Inhibition of GSK-3β activities has
previously been reported to be a nodal point in protec-
tion of the heart towards ischemia-reperfusion injury
through inhibition of the mitochondrial transition pore
(Juhaszova et al. 2004; Juhaszova et al. 2009). Third,
the transcriptome of CCN2-stimulated cardiac myocytes
revealed induction of gene expression programs with
recognized cytoprotective functions in hypoxia/reoxyge-
nation injury and oxidative stress. In this respect, sev-
eral of the most substantially up-regulated genes in
cardiac myocytes treated with rhCCN2 have previously
been reported to confer cardioprotection towards ische-
mia/reperfusion injury, such as for example WISP1/
CCN4, GDF-15, and lipocalin-2 (Venkatesan et al.
2010; Xu et al. 2006; Roudkenar et al. 2009;). In
congruence with the ultimate role of Akt/GSK-3β sig-
naling in CCN2-mediated cytoprotection, as demon-
strated in this study, CCN2-stimulated induction of
WISP1/CCN4 and GDF15 expression were also sensi-
tive to inhibition of Akt. Thus, the gene expression
signature caused by prolonged exposure to CCN2 ap-
parently corroborates the immediate protective effects
Doxorubicin-induced cardiac myocyte damage
































































































































Fig. 7 Cardiac myocyte cell
death quantified by analysis of
release of lactate dehydrogenase
(LDH) and adenylate kinase ac-
tivities into the cell culture medi-
um. a Viability of cardiac
myocytes pretreated in the ab-
sence (Dox) or presence (Dox +
CCN2) of 200 nmol/L rhCCN2
for 20 h, and then incubated with
15 μmol/L doxorubicin for 20 h.
b Viability of cardiac myocytes
preincubated in the absence
(Control hypoxia) or presence
(CCN2) of 200 nmol/L rhCCN2
for 20 h, then exposed to hypoxia
(1 % O2) for four hours, before
one hour reoxygenation with
ambient O2 (simulated ischemia/
reperfusion). Cell viability is
expressed as the mean ± SEM
percentage of the survival of
untreated control cells (Control/
Control normoxia), n06 in each
group, *p<0.05. The figure is
representative of three indepen-
dent experiments
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of Akt/GSK-3β phosphokinase signaling. Yet, the ob-
servation that inhibition of PI3-kinase/Akt signaling did
not prevent all CCN2-mediated gene regulation may
suggest that CCN2 also activates other signaling path-
ways. The latter contention would be consistent with the
more robust cardioprotection observed in Langendorff-
perfused hearts from transgenic mice with cardiac-
restricted overexpression of CCN2 versus that of hearts
exposed to rhCCN2 immediately before ischemia
(Ahmed et al. 2011). However, activation of the Akt/
GSK-3β phosphokinase cascade was the only confidently
Fig. 9 Heat maps illustrating relative expression levels of differential-
ly expressed genes relating to the Gene Ontology terms “response to
wounding” and “anti-apoptosis” in cardiac myocytes stimulated in the
absence or presence of rhCCN2 (200 nmol/L) for 48 h. Yellow/red and





























































































































































Fig. 8 Analysis of cell death quantified by LDH and adenylate kinase
released into the cell culture medium of cardiac myocytes exposed to
hypoxia (1 % O2) for four hours and subsequently one hour reoxyge-
nation to ambient O2 (simulated ischemia/reperfusion). a-b Viability of
cells preincubated for 20 h in the absence (Control hypoxia) or pres-
ence of 200 nmol/L rhCCN2 (CCN2), or with 200 nmol/L rhCCN2 and
10 μmol/L of PI3-kinase inhibitor LY294002 (CCN2 + LY294002), or
200 nmol/L rhCCN2 and 10 μmol/L LY303511 (Negative control with
respect to PI3-kinase inhibitory activity of LY294002) (CCN2 +
LY303511), before exposure to hypoxia and reoxygenation. Control
cells were not exposed to hypoxia or rhCCN2 (Control normoxia). Cell
viability is expressed as the mean ± SEM percentage of the survival of
untreated control cells, n06 in each group, *p<0.05 vs. control. c
TUNEL of cells preincubated in the absence or presence of
200 nmol/L rhCCN2 for 20 h, then exposed to hypoxia and subse-
quently reoxygenation. Histogram demonstrates mean of three inde-
pendent assays (number of % apoptotic cells from a minimum of 10
visual fields per assay). Data are mean ± SEM. *p<0.05 vs. control. d
Example of TUNEL positive cardiac myocytes. e Example of TUNEL
negative cardiac myocytes
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activated signaling pathway observed upon exposure of adult
cardiac myocytes to rhCCN2. In other cell types CCN2 has
been reported to activate TrkA receptor signaling, p38 or
ERK1/2 MAP kinases, or SMAD2/3 signaling depending
on cellular context (Rachfal and Brigstock 2005).
Neither of these pathways was stimulated by CCN2 in
the adult cardiac myocytes. Thus, CCN2-engendered
signaling appears to be dependent on both cell type,
and extent of cell differentiation. Although a receptor
for CCN2 has not yet been convincingly characterized,
the competitive inhibition of CCN2-stimulated activation
of Akt by overexpression of the PH domain of GRK2ct,
as shown in this study, demonstrates that direct action
of CCN2 on cardiac myocytes elicits mechanisms that
activate Akt at the plasma membrane interface.
Gene ontology analysis of the CCN2-stimulated tran-
scriptome of cardiac myocytes revealed activation of
cellular and biological processes that help increasing
the tolerance of cardiac myocytes towards hypoxia/reox-
ygenation-induced injury, i.e. anti-apototic genes, stress-
responsive genes, and wound-response genes. A recent
study reported that recombinant hCCN2 induces pro-
fibrotic and pro-inflammatory factors in the H9c2 cardi-
ac myocyte cell line (Wang et al. 2010). The gene
ontology analysis of the CCN2-mediated transcriptome
of fully differentiated, adult cardiac myocytes did not
disclose statistically significant regulation of pro-
inflammatory or pro-fibrotic gene programs. Yet, specif-
ic proinflammatory cytokines, for example interleukin-6
and interleukin-1β, were found to be slightly upregu-
lated (fold change 1.2 and 1.3, respectively), while
TNF-α and interleukin-8 mRNA levels were not regu-
lated in the DNA microarray of CCN2-stimulated cardi-
ac myocytes in our study. Such proinflammatory factors
Table 1 The most up- and
down-regulated genes from the
DNA microarray analysis of
cardiac myocytes cultured in the
absence (n06) or presence (n06)
of 200 nmol/L CCN2 for 48 h
Description Symbol Fold change
WNT1 inducible signaling pathway protein 1 Wisp1 5,9
Growth differentiation factor 15 Gdf15 4,8
Lipocalin 2 Lcn2 4,3
Solute carrier family 40 (iron-regulated transporter), member 1 Slc40a1 4,1
Adenosine monophosphate deaminase 3 Ampd3 3,7
Myosin, light polypeptide kinase 2, skeletal muscle Mylk2 3,4
Breakpoint cluster region Bcr 3,3
Chemokine (C-X-C motif) ligand 1 Cxcl1 3,3
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 3 Dyrk3 3,3
Ankyrin repeat domain 10 Ankrd10 3,1
Cytokine inducible SH2-containing protein Cish 3,1
Feminization 1 homolog b (C. elegans) Fem1b 3,1
Sulfiredoxin 1 homolog (S. cerevisiae) Srxn1 3,0
Teashirt zinc finger family member 1 Tshz1 3,0
Solute carrier family 6 (neurotransmitter transporter, taurine), member 6 Slc6a6 3,0
Lymphocyte antigen 6 complex, locus A Ly6a −8,3
Radical S-adenosyl methionine domain containing 2 Rsad2 −6,3
Aquaporin 1 Aqp1 −5,6
Interferon-induced protein with tetratricopeptide repeats 3 Ifit3 −4,8
Lymphocyte antigen 6 complex, locus C1 Ly6c1 −4,7
Lymphocyte antigen 6 complex, locus E Ly6e −4,7
Interferon, alpha-inducible protein 27 like 2A Ifi27l2a −4,6
Claudin 5 Cldn5 −4,6
Adenylate cyclase 4 Adcy4 −4,0
Thymic stromal lymphopoietin Tslp −3,8
Serine (or cysteine) peptidase inhibitor, clade A, member 3N Serpina3n −3,8
Caveolin-1, caveolae protein Cav1 −3,8
Histocompatibility 2, T region locus 23 H2-T23 −3,8
Multimerin 2 Mmrn2 −3,7
Lysozyme 1 Lyz1 −3,6


























Fig. 10 Heat maps illustrating
relative expression levels of
differentially expressed genes
relating to the Gene Ontology
terms “response to stress” and
“apoptosis” (apoptosis-related
genes) in cardiac myocytes
stimulated in the absence or
presence of rhCCN2
(200 nmol/L) for 48 h. Yellow/
red and blue colors indicate
expression levels above and
below average, respectively
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may also be survival factors in ischemia/reperfusion
injury despite their more dubious role upon prolonged
presence. It should be noted, however, that transgenic
mice with cardiac-restricted overexpression of CCN2 did
not reveal an inflammatory morphologic substrate in the
heart (Ahmed et al. 2011).
An emerging issue related to the use of purified, recom-
binant human CCN2 is to what extent CCN2 was the active
principal or substance in the purified preparation that stim-
ulated phosphorylation of Akt and GSK-3β. Concentration
effect curves of CCN2-stimulated phosphorylation of Akt
and GSK-3β in Rat-2-fibroblasts revealed half-maximum
stimulation at approximately 200 nmol/L of CCN2, with
maximal effective concentrations between 500 nmol/L
and 1 μmol/L. CCN2 stimulated phosphorylation of
Akt and exerted cytoprotective actions in adult cardiac
myocytes within the same range of concentrations.
Furthermore, a peptide from the c-terminal region of
CCN2 (11.2 kDa C-terminal fragment of human
CCN2), previously reported to exert agonist effects,
was a partial agonist with respect to phosphorylation
of Akt and GSK-3β, albeit substantially less potent than
the full-length protein. Indeed, this study is first to
provide data of efficacy and potency relationships of
the the C-terminal CCN2 fragment versus full-length
CCN2. In addit ion, peptides derived from the
Thrombospondin and IGFBP homology domains of
CCN2 inhibited CCN2-stimulated phosphorylation of
Akt and GSK-3β. The two peptides exerted additive
effects, suggesting that competition at several epitopes
of CCN2 were involved in inhibition of CCN2-stimulated
phosphorylation of Akt and GSK-3β. Thus, the data consis-
tently indicate that recombinant CCN2 was the active princi-
pal in the purified preparation. The similar potencies and
efficacies of glycoylated versus deglycosylated rhCCN2 indi-
cate that glycosylation of CCN2 does appear to affect
signaling per se, but may rather affect other properties
of CCN2, for example binding of extracellular matrix
proteins and distribution among tissues.
CCN2-stimulated increase of phospho-Akt (Ser473) lev-
els has previously been reported in neonatal rat cardiac
myocytes (Hayata et al. 2008). In the same study
CCN2 also stimulated phosphorylation of several mem-
bers of the MAP kinase family, that is ERK1/2, JNK,
and P38. However, it is well known that neonatal car-
diac myocytes respond very differently compared with
fully differentiated adult cardiac myocytes. Interestingly,
CCN1, another member of the CCN-family, has also
been reported to protect neonatal rat cardiac myocytes
from oxidative stress via an Akt-sensitive signaling
pathway (Yoshida et al. 2007). Furthermore, WISP1/
CCN4 ameliorated doxorubicin-induced death of adult
mouse cardiac myocytes by several mechanisms, includ-
ing inhibition of p38 and JNK MAP kinases, as well as
activation of Akt (Venkatesan et al. 2010). However, to
what extent phosphorylation and activation of Akt is a
class specific effect of CCN-proteins is currently not
known. These issues await recombinant expression and
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Fig. 11 Histograms of
quantitative real-time RT-PCR
analyses of mRNA levels of
WISP1, GDF15, Lipocalin-2,
and DYRK3, relative to 18S
rRNA levels in cardiac myo-
cytes incubated for 48 h without
rhCCN2, with 200 nmol/L
rhCCN2, or with 200 nmol/L
rhCCN2 in combination with
10 μmol/L API-2. Data are
mean ± SEM, n03 in each
group, *p<0.05
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In conclusion, this study demonstrates that adult cardiac
myocytes are direct targets of CCN2, and that CCN2 stim-
ulates the Akt/GSK-3β signaling pathway, with resulting
induction of a transcriptome that increases the tolerance of
cardiac myocytes towards hypoxia/reoxygenation injury and
oxidative stress. Thus, recombinant CCN2, or a compound
with its agonist properties, may be pursued as a putative
novel pharmacologic intervention in acute coronary syn-
dromes in order to reduce infarct size.
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